Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer
Work
Year: 2023
Type: article
Abstract: Background Before 2018, there was no standard of care for non-metastatic (M0) castration resistant prostate cancer nmCRPC. Androgen receptor antagonists (ARAs) were commonly used sequentially nmCRPC.... more
Source: The Oncologist
Institutions National Cancer Institute, Columbia University Irving Medical Center, Temple University Health System, Fox Chase Cancer Center, Rutgers, The State University of New Jersey +1 more
Cites: 11
Cited by: 7
Related to: 10
FWCI: 3.249
Citation percentile (by year/subfield): 100
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: gold
APC paid (est): $3,494
Funder National Cancer Institute